Knopman, David S. http://orcid.org/0000-0002-6544-066X
Laskowitz, Daniel T.
Koltai, Deborah C.
Charvet, Leigh E.
Becker, Jacqueline H.
Federman, Alex D.
Wisnivesky, Juan
Mahncke, Henry
Van Vleet, Thomas M.
Bateman, Lucinda
Kim, Dong-Yun
O’Steen, Ashley
James, Melissa
Silverstein, Adam
Lokhnygina, Yuliya
Rich, Jennifer
Feger, Bryan J.
Zimmerman, Kanecia O.
Funding for this research was provided by:
National Institutes of Health (1OT2HL156812-01 (OTA-20-011))
Article History
Received: 2 January 2024
Accepted: 7 May 2024
First Online: 17 May 2024
Declarations
:
: The RECOVER-NEURO trial protocol and informed consent document were approved by the Advarra Institutional Review Board (Pro00070287). Any amendments to the protocol will be communicated to relevant parties via meetings and emails. All participants will provide written, informed consent to study site personnel before beginning study-related activities. This consent will also cover a review of participants’ medical records and collection of biospecimens for the biorepository.
: Not applicable
: DSK reports no conflicts with respect to the current work. Dr. Knopman serves on a Data Safety Monitoring Board for the Dominantly Inherited Alzheimer Network Treatment Unit study. He served on a Data Safety Monitoring Board for a tau therapeutic for Biogen (until 2021) but received no personal compensation. He was an investigator in clinical trials sponsored by Biogen, Lilly Pharmaceuticals, and the University of Southern California, a trial in frontotemporal degeneration with Alector. He has served as a consultant for Roche, Samus Therapeutics, Magellan Health, Biovie, and Alzeca Biosciences but receives no personal compensation. He receives funding from the NIH.JW has received an honorarium from Sanofi, PPD, Prospero, and Banook and research grants from Sanofi, Regeneron, Axella, and Arnold Consultants.LEC has consulted for Johnson & Johnson, Neuroelectrics, and YBrain.HM and TVV are employees of and hold stock/stock options in Posit Science, the developers of BrainHQ.